Enanta Pharmaceuticals (ENTA) Return on Capital Employed (2013 - 2026)
Enanta Pharmaceuticals (ENTA) posted Return on Capital Employed of 21.91% for Q1 2026, up 21.93% on a QoQ basis from 28.06% in Q4 2025, and up 1332.0% year-over-year from 1.53% in Q1 2025.
Enanta Pharmaceuticals (ENTA) Return on Capital Employed (2013 - 2026) Analysis & Trends
Enanta Pharmaceuticals' Return on Capital Employed history runs 14 years deep, the most recent figure standing at 21.91% for Q1 2026.
- Quarterly Return on Capital Employed rose 1332.0% year-over-year to 21.91% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21.91% (up 1332.0% YoY) and the FY2025 annual result came in at 30.47%, up 316.0% from the prior year.
- Return on Capital Employed was 21.91% for Q1 2026 at Enanta Pharmaceuticals, up from 28.06% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 21.91% in Q1 2026 and bottomed at 42.34% in Q1 2023.
- A 5-year average of 34.86% and a median of 35.31% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 1465 bps — and 2026, when it soared 1332 bps.
- Enanta Pharmaceuticals' Return on Capital Employed stood at 36.47% in 2022, then retreated by 2 bps to 37.1% in 2023, then climbed by 5 bps to 35.19% in 2024, then grew by 20 bps to 28.06% in 2025, then grew by 22 bps to 21.91% in 2026.
- Business Quant data shows ENTA's Return on Capital Employed at 21.91% in Q1 2026, 28.06% in Q4 2025, and 35.22% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Enanta Pharmaceuticals | 369.97 Mn | 206.20 Mn | - | -21.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.91% |
| Dec 31, 2025 | -28.06% |
| Sep 30, 2025 | -35.22% |
| Jun 30, 2025 | -36.20% |
| Mar 31, 2025 | -35.23% |
| Dec 31, 2024 | -35.19% |
| Sep 30, 2024 | -36.85% |
| Jun 30, 2024 | -35.31% |
| Mar 31, 2024 | -36.95% |
| Dec 31, 2023 | -37.10% |
| Sep 30, 2023 | -32.99% |
| Jun 30, 2023 | -38.88% |
| Mar 31, 2023 | -42.34% |
| Dec 31, 2022 | -36.47% |
| Sep 30, 2022 | -35.34% |
| Jun 30, 2022 | -34.99% |
| Mar 31, 2022 | -33.55% |
| Dec 31, 2021 | -31.78% |
| Sep 30, 2021 | -26.83% |
| Jun 30, 2021 | -22.21% |